Study Comparing Safety and Drug Behavior of a Single Dose of AD-115A and AD-1151 in Healthy Adults

What this Trial Is About

Researchers are evaluating the safety and how the body processes two different oral drugs, AD-115A and AD-1151, in healthy adults. This study focuses on comparing these two treatments to understand their pharmacokinetics and safety when taken as a single dose while fasting. The trial is designed as a randomized, open-label, crossover study to carefully assess these characteristics in adult participants. Participants will take a single 200 mg oral dose of either AD-115A or AD-1151, depending on their assigned sequence in the study. The trial consists of two periods where each participant receives both drugs in a randomized order with a washout period in between. This approach helps compare the effects of each drug within the same individual. During the study, researchers will monitor drug levels in the blood over 24 hours to measure the maximum concentration and the overall exposure to the drug. Safety assessments will also be conducted throughout the trial. Participants will be required to fast before dosing, and the study will include regular visits for blood sampling and health evaluations. The entire participation will cover both dosing periods and follow-up assessments as scheduled by the trial.

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'